The FDA's rebuff of Replimune comes a day after the agency similarly called into question the Phase 3 trial for Capricor’s ...
Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.
Good morning and welcome to the Replimune Fiscal Year Fourth Quarter 2025 Financial Results and Corporate Update Conference Call. Currently, all participants are in listen-only mode. This call is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results